Oral Anticoagulation and the Devil You Don't Know vs the Devil You Do: Safety of NOACs vs Warfarin
|
|
- Elmer Cook
- 8 years ago
- Views:
Transcription
1 Oral Anticoagulation and the Devil You Don't Know vs the Devil You Do: Safety of NOACs vs Warfarin Charles V. Pollack, Jr., M.A., M.D., FACEP, FAAEM, FAHA, FCPP Professor and Chairman Department of Emergency Medicine Pennsylvania Hospital University of Pennsylvania Philadelphia
2 Disclosure of Significant Relationships with Relevant Commercial Interests Charles V. Pollack, Jr., MA, MD No promotional activities Consultant to Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, Pfizer, Durata, Luitpold Research support from Luitpold Pharmaceuticals, AstraZeneca
3 Oral Anticoagulation and the ED Initiate therapy for VTE (DVT and PE) Parenterally with unfractionated heparin, enoxaparin, dalteparin, fondaparinux, coupled with (and bridging to) warfarin Rivaroxaban (only FDA approved option to date, does not require bridging) Apixaban expected to be approved 2014, does not require bridging Dabigatran and edoxaban may be approved, do require bridging Initiate (or facilitate) anticoagulation for SPAF Mostly done by cardiologists or hospitalists Bridging not usually done Warfarin, rivaroxaban, apixaban, dabigatran Manage patients with ED presentations (including bleeding complications) who are being treated for VTE, on SPAF, or with mechanical valves, etc, with any of these agents
4 Evolving Approach to Anticoagulation Direct Xa Inhibitors Oral 2000s Direct thrombin Inhibitors Indirect Xa Inhibitors LMWH VKA Heparin Class of drug Courtesy F. Michota MD.
5 Inhibition of Vitamin K Dependent Coagulation Factors by Warfarin Intrinsic XII Extrinsic XI IX TF Protein C & S VIII Xa VII V II IIa Fibrinogen Fibrin Clot Weitz JI, et al. Chest. 2001;119(1 suppl):95s-107s; Gulseth MP, et al. Am J Health Syst Pharm. 2008;65(16):
6 Selective Factor Inhibition Novel Oral Anticoagulants Intrinsic XII Extrinsic XI IX TF Xa is an amplifica,on step Protein C & S VIII II Xa V IIa VII Rivaroxaban Apixaban Edoxaban Dabigatran (also inhibits clot- bound thrombin) Fibrinogen Fibrin Clot Blommel ML, et al. Am J Health-Syst Pharm. 2011;68: ; Gulseth MP, et al. Am J Health-Syst Pharm. 2008;65: ; Nutescu E. Am J Health-Syst Pharm. 2012;69: ; Palladino M, et al. Am J Hematol. 2012;87(suppl 1): ; Wittkowsky AK. Pharmacotherapy. 2011;31:
7 New Oral Anticoagulant Development Nonvalvular Atrial Fib and VTE In Development XARELTO (rivaroxaban) Bayer/JNJ QD/BID, fxa Inhibitor ORS 3Q11 AF 4Q11 DVT PE 4Q12 Pradaxa (dabigatran) Boehringer Ingelheim QD/BID, DT Inhibitor AF 3Q10 DVT PE App 4Q13 Eliquis (apixaban) BMS/Pfizer BID, fxa Inhibitor AF 4Q12 DVT PE App 4Q14 Lixiana (edoxaban) Daiichi Sankyo QD, fxa Inhibitor AF Antic 4Q14 DVT PE Antic 4Q14 Betrixaban Portola QD, fxa Inhibitor 7 Med Ill Antic 2Q16
8 NOACs in clinical trials SPAF, compared to warfarin: Dabigatran (150): superior efficacy all stroke, ischemic stroke; noninferior major bleed; superior all-cause mortality Rivaroxaban: noninferior efficacy all stroke, ischemic stroke; noninferior major bleed; noninferior all-cause mortality Apixaban: superior efficacy all stroke, noninferior ischemic stroke; superior major bleed; superior all-cause mortality All three had lower rates of intracranial bleeding compared to warfarin VTE treatment, compared to enox or UFH bridge to warfarin: Rivaroxaban: noninferior efficacy and safety Apixaban (not yet approved): noninferior efficacy, superior safety Dabigatran (not approved): noninferior efficacy and safety Edoxaban (not approved): noninferior efficacy, superior safety
9 Overview and Pharmacology Novel Oral Anticoagulants Apixaban 1-4 Dabigatran 1,5 Rivaroxaban 1,6 Drug class Direct factor Xa inhibitor Direct factor IIa inhibitor Direct factor Xa inhibitor Bioavailability 50% 3%-7% 80%-100% for 10 mg dose 66% for 20 mg dose Onset of anticoagulant effect Within 3 hours Within 2 hours Within 4 hours CYP metabolism 25% CYP3A4 No 30% CYP3A4, CYP2J2 Renal excretion 27% 80% 36% Half-life 12 hours hours 5-9 hours Dosage form Tablet Capsule Tablet Dosing frequency BID BID BID or once daily CYP = cytochrome P Wittkowsky AK. Pharmacotherapy. 2011;31: Zhang D, et al. Drug Metab and Disp. 2009;37: Eliquis (apixaban). Available at: curl=pages/medicines/human/medicines/002148/human_med_ jsp&mid=wc0b01ac058001d124; 4. Eliquis (apixaban) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company. December 2012; 5. Pradaxa (dabigatran etexilate mesylate) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc. November 2012; 6. Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; November 2012.
10 Safety Concerns with NOACs Conundrum # 1 Patients on NOACs do not require routine anticoagulation monitoring. Conundrum # 2 Warfarin is safer than the NOACs because it can be reversed. Question: What is the best ED strategy for managing oral anticoagulant-related hemorrhage or intracranial bleed?
11 Conundrum # 1: Monitoring NOACs When dosed properly by indication and renal function, routine monitoring not required for NOACs used in treating VTE or providing SPAF At times, especially in ED when evaluating bleeding or bleeding concern in patients taking a NOAC, measurement of anticoagulation activity is desirable Standard PT/INR and aptt measures will not quantitatively assess anticoagulation with NOACs
12 Role of Coagulation Testing a for NOACs Apixaban 1-3 Dabigatran 1,2 Rivaroxaban 1-3 Ecarin clotting time (ECT) NA 5.2x baseline NA Anti-Xa activity NR NA 22% with 5 mg 68% with 30 mg Thrombin time (TT) NA 27x baseline NA Prothrombin time (PT) 2,4 Range: There are no commercially available anti-xa assays calibrated for NOACs, only for UFH/LMWH Little effect at clinically relevant plasma concentration Range: INR 1.5x baseline 1.8x baseline NR Activated partial thrombo-plastin time (aptt) 1.2x baseline 2.3x baseline 1.8x baseline HepTest NA NA 2.8x baseline Preferred Test Anti-Xa, mptt, HepTest ECT b, TT Anti-Xa c, PT d a Useful for assessing: compliance, drug interactions, overdose, use in renal and/or hepatic impairment; NOT to be used routinely for dose adjustments; b not readily available; c can use same assay as enoxaparin; d reagent dependent NA = not applicable; NR = not reported; mptt = modified prothrombin time 1. Eriksson BI, et al. Clin Pharmacokinet. 2009;48:1-22; 2. Barrett YC, et al. Thromb Haemost. 2010;104: ; 3. Kubitza D, et al. Eur J Clin Pharmacol. 2005; 61: ; 4. van Ryn J, et al. Thromb Haemost. 2010;103:
13 Assessing Intensity of Anticoagulation Effects Drug Present Quantitative Test Sensitivity: PT vs aptt No or Limited Effect Apixaban/Rivaroxaban? Chromogenic anti-factor Xa High sensitive INR Chromogenic anti-factor Xa PT > aptt ECT, TT Thrombin time Dabigatran? Dilute thrombin time or chromogenic ECT aptt > PT (point-of-care INR > central lab) Lindhoff-Last E, et al. Ther Drug Monit. 2010;32: ; Lindahl TL, et al. Thromb Haemost. 2011;105: ; van Ryn J, et al. Am J Med. 2012;125: ; van Ryn J, et al. Thromb Haemost. 2010;103:
14 Conundrum # 2: Reversal of Warfarin It is inaccurate to refer to use of vitamin K as reversing warfarin-induced anticoagulation Use more accurate Anticoagulation with warfarin results from depletion of vitamin K-dependent clotting factors II, VII, IX, and X, and proteins C and S terminology: Administration of vitamin K allows liver to begin synthesizing these factors again REVERSE Endogenous repletion and correction of INR may take up to 24 h or longer, depending on patient s liver health and overall physiologic status If goal is hemostasis and not normal INR, exogenous repletion in addition to vitamin K must be provided RESUSCITATE AND REPLETE There is no analogue to Vitamin K treatment in patients taking NOACs Half-life of all NOACs significantly shorter than that of warfarin, so intensive support should be required for a shorter interval
15 Step 1: Resuscitate + Fresh-Frozen Plasma ABCs - Replete volume for BP (and, if needed, ICP) control - Type and cross-match - Stop interruptible blood loss (tamponade, endoscopy, interventional radiology) Decon - Consider activated charcoal - (dabigatran only) consider hemodialysis FFP 1 - Partially restores clotting factor levels - Blood typing required - Must be thawed at 30 o 37 o C for min prior to use - Dosing is 15 ml/kg (infusion 3 6 h), which is a large amount of colloid volume Special considerations: Potential for circulatory overload Small risk of: viral transmission, passive alloimmune thrombocytopenia, anaphylaxis, septicemia 1. Cervera A, et al. J Neurol. 2012;259:
16 Effects of Repletion Agents on Anticoagulant Activity in an Ex-Vivo Model Measured Effect on Thrombin Generation: AUC, Peak, Time to Peak, and Lag Time Nonspecific Reversal Agent rfviia: NovoSeven 0.5,1.5,3 ug/ml apcc: FEIBA 0.25,0.5,1,2 U/mL 4-factor PCC a : Kanokad 0.25,0.5,1 U/mL Conclusions: If immediate reversal is needed, currently no clear evidence for any reversal agent clinically FEIBA effective for rivaroxaban ex-vivo, but higher doses are associated with more thrombin generation; clinically may cause more thrombosis Marlu R, et al. Thromb Haemost. 2012;108: Not tested Not tested Not tested Apixaban Dabigatran 150 mg + (lag time) + (lag time) + (increased AUC) Rivaroxaban 20 mg + (lag time) +++ (AUC, peak, lag time, and time to peak) ++ (strongly corrected AUC, modest peak) a PCCs contain significant quantities of factors II, IX, and X; 4-factor PCCs (approved but not yet available in the US) also contain factor VII rfviia = recombinant activated clotting factor VII
17 4-Factor PCC now FDA-Approved Repletes II, VII, IX, and X, plus proteins C and S (VII lacking in 3-factor PCC) Lower volume infusion required than FFP, with ~25x the factor concentration To date, much more study in treating warfarin-related bleeding than NOACs Reduces INR faster than FFP Restores factor levels faster than FFP 7x faster infusion time than FFP 87% reduction in volume of infusion compared to FFP Similar safety profile to FFP Sarode R, et al. Circulation Aug 9. [Epub ahead of print].
18 Managing Bleeding in Patients Receiving Apixaban Apixaban No established way to reverse anticoagulant effect, which persists ~24h after last dose Because of high plasma protein binding, apixaban is not dialyzable Protamine sulfate and vitamin K do not affect anticoagulant activity No experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) No scientific rationale for reversal No experience with systemic hemostatics (desmopressin and aprotinin) Use of procoagulant reversal agents such as prothrombin complex concentrate, activated prothrombin complex concentrate, or rfviia may be considered but have not been evaluated in clinical studies Activated oral charcoal reduces adsorption, thereby lowering apixaban plasma concentration Eliquis (apixaban) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; December 2012.
19 Managing Bleeding in Patients Receiving Dabigatran Dabigatran Inhibits last step in coagulation cascade; any agent that stimulates this cascade or replaces coagulation factors proximal to thrombin will not compensate for the profound terminal hemostatic defect 1 Activated charcoal or gastric lavage early after ingestion 1 Completely adsorbs lipophilic drug in solution 1 PCC not known to mitigate anticoagulant effect 1 Consider activated PCC (very high doses) 2 rfviia recommended in PI for life-threatening bleeding 1,2 Triggers thrombin generation Has not been shown to reverse bleeding complications Has a very short half-life Expensive Associated with otherwise avoidable thromboembolism Acute hemodialysis for extreme cases 1 Only 35% of dabigatran protein bound 6 hours of dialysis decreased thrombin clotting time from 150 to 68 seconds 1. Schulman S, et al. Blood. 2012;119: ; 2. Ageno W, et al. Chest. 2012;141(suppl 1):e44s-e88s.
20 Managing Bleeding in Patients Receiving Rivaroxaban May be effective: Rivaroxaban All measurable anticoagulant effect reversed by 4-factor PCC in healthy male volunteers 1 can use 50 IU/kg in the case of acute major bleeding 3-factor PCC still available in US 1 Not dialyzable because highly protein bound (92%-95%) 2 Activated oral charcoal may be considered as it reduces absorption 3 1. Schulman S, et al. Blood. 2012;119: ; 2. Ageno W, et al. Chest. 2012;141(suppl 1):e44s-e88s; 3. Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; Nov
21 Managing NOAC-related bleeding Practical Considerations Intracranial bleeds are significantly less common with NOACs than with warfarin The BEST strategy to treat bleeding is to prevent it Primum non nocere Half-lives of NOACs are short if the patient has normal renal function Appropriate patient selection PCCs should be used when clinically appropriate. The risk benefit of thrombosis must be considered Dialysis is indicated for severe bleeding with dabigatran Camm JA, et al. Eur Heart J. 2012;33: ; Schulman S, et al. Blood. 2012;119:
22 Summary NOACs are safer and more predictable than warfarin Shorter half-life Significantly lower rates of ICH than warfarin Cannot be readily assessed/monitored No oral anticoagulant-based major bleeding event can simply be reversed
48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationNew anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationStop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
More informationDisclosure. Warfarin
Disclosure No conflicts of interest to disclose Reversal Strategies for Novel Oral Anticoagulants Noelle de Leon, PharmD, BCPS Critical Care Pharmacist, Department of Pharmaceutical Services Assistant
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationNew Oral Anticoagulants
Laboratory Monitoring of New Oral Anticoagulants.....What you need to know Rita Selby MD Medical Director, Coagulation Laboratories Uniersity Health Network & Sunnybrook HSC Uniersity of Toronto The 15
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationSTARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationDABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
More informationReversing the New Anticoagulants
Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today
More informationThe management of cerebral hemorrhagic complications during anticoagulant therapy
The management of cerebral hemorrhagic complications during anticoagulant therapy Maurizio Paciaroni Stroke Unit Division of Cardiovascular Medicine University of Perugia - Italy Perugia Stroke Registry
More informationPost-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
More informationLaboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)
Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Dr. Art Szkotak artur.szkotak@albertahealthservices.ca University of Alberta Hospital Edmonton, AB NOACs Direct Thrombin Inhibitors (DTI):
More informationReversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug
More informationDisclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
More informationTo assist clinicians in the management of minor, major, and/or life-threatening bleeding in patients receiving new oral anticoagulants (NOACs).
MANAGEMENT OF BLEEDING IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To assist clinicians
More informationUSE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)
USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN) TARGET AUDIENCE: All Canadian health care professionals:
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationSession 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
More informationThrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
More informationMANAGING BLEEDING IN THE
MANAGING BLEEDING IN THE SETTING OF NEW ANTICOAGULANTS: HOW DO OLD METHODS MEASURE UP? Michelle Zeller MD Clinical Hematology Fellow November 5th, 2011 A FRIDAY NIGHT ON-CALL WITH DR. B. LUD Very keen
More informationLAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationNovel Anticoagulants
Novel Anticoagulants Mark T. Reding, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation Director, Center for Bleeding and Clotting Disorders University of Minnesota
More informationNow We Got Bad Blood: New Anticoagulant Reversal
Now We Got Bad Blood: New Anticoagulant Reversal Kellie Rodriguez, PharmD, BCPS PGY2 Emergency Medicine Pharmacy Resident UF Health Jacksonville January 2016 Objectives 1. Review current treatment strategies
More informationNnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
More informationNew Anticoagulation Agents and Their Reversal Agents. Objectives. Background 12/21/2015
New Anticoagulation Agents and Their Reversal Agents Jay Hazelcorn, Pharm.D. PGY-1 Pharmacy Resident Broward Health Medical Center Objectives Review the pharmacology, indications, and place in therapy
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More information3/17/2014. No conflicts of interest to report
No conflicts of interest to report Patrick M. Lewis, Pharm.D., BCPS, CACP Lahey Hospital & Medical Center Burlington, MA April 1 st 2014 Parts of this presentation discuss off-label use of reversal agents.
More informationDISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose
DISCLOSURES CATEGORY Employment Research support Scientific advisory board Consultancy Speakers bureau Major stockholder Patents Honoraria Travel support Other CONFLICT No conflict of interest to disclose
More informationThe Anticoagulated Patient A Hematologist s Perspective
The Anticoagulated Patient A Hematologist s Perspective Deborah M. Siegal MD MSc FRCPC Clinical Scholar Division of Hematology and Thromboembolism Thrombosis Canada Research Fellow McMaster University
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationWarfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
More informationReversal of Old and New Antithrombotic Drugs. Mike Makris
Reversal of Old and New Antithrombotic Drugs Mike Makris BCSH guidelines Guidelines on oral anticoagulation with warfarin fourth edition 1 Guideline on the urgent or emergency reversal of antithrombotic
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationThe Brave New (Anticoagulant) World
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
More informationAnticoagulation Essentials! Parenteral and Oral!
Anticoagulation Essentials! Parenteral and Oral! Anti-Xa and Anti-IIa! Parenteral Anticoagulants! Heparin family (indirect anti-xa and anti-iia):! UFH! LMWH (enoxaparin, fondaparinux)! Direct thrombin
More informationImpact of new (direct) oral anticoagulants in patient blood management
Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationDe effecten van Cofact op Rivaroxaban plasma in trombine generatie assays
De effecten van Cofact op Rivaroxaban plasma in trombine generatie assays In vitro assessment, using thrombin generation, of the applicability of Prothrombin Complex Concentrate as an antidote for Rivaroxaban
More informationWhat to do in case of hemorragia. L Camoin Jau Service d Hématologie APHM Marseille
What to do in case of hemorragia with NOAC? L Camoin Jau Service d Hématologie APHM Marseille Disclosure Boehringer Bayer Daishi Sanofi BMS Pharmacodynamic and kinetic properties of new oral anticoagulants.
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationNew Oral Anticoagulant Drugs What monitoring if any is required?
New Oral Anticoagulant Drugs What monitoring if any is required? Michelle Williamson Supervising Scientist High Throughput Haematology Pathology Queensland PAH Laboratory Overview Background What new oral
More informationNew Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationDisclosures. Objective (NRHS) Self Assessment #2
Development and Implementation of a Protocol for Reversing the Effects of Anticoagulants for Use in a Community Hospital Samantha Sepulveda, Pharm.D. PGY1 Pharmacy Resident Norman Regional Health System
More informationCHALLENGES AND OPPORTUNITIES IN CLINICAL USE OF THE NEW ORAL ANTICOAGULANTS. Amy Giovino, PharmD Formulary Coordinator Sarasota Memorial Hospital
CHALLENGES AND OPPORTUNITIES IN CLINICAL USE OF THE NEW ORAL ANTICOAGULANTS Amy Giovino, PharmD Formulary Coordinator Sarasota Memorial Hospital 1 2 Disclosure I do not have a vested interest in or affiliation
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationNew Oral AntiCoagulants (NOAC) in 2015
New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research
More informationEMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013
EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults February, 2013 1 Quick Index To Reversal Recommendations Anti-Platelet Medications Page P2Y12
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationAnticoagulants. Denver Health April 12, 2011
New Oral Anticoagulants Rebecca Hanratty, MD Denver Health April 12, 2011 Overview Why we need alternatives to warfarin Review of the 3 new oral anticoagulants Results from major trials: Thromboprophylaxis
More informationQUICK REFERENCE. Mary Cushman 1 Wendy Lim 2 Neil A Zakai 1. University of Vermont 2. McMaster University
QUICK REFERENCE Clinical Practice Guide on Antithrombotic Drug Dosing and Management of Antithrombotic Drug- Associated Bleeding Complications in Adults February 2014* Mary Cushman 1 Wendy Lim 2 Neil A
More informationMonitoring of new oral anticoagulants
Monitoring of new oral anticoagulants Jonathan Douxfils, Bernard Chatelain September 27th, 2012 1 Content Introduction Monitoring of NOACs Why? Dabigatran etexilate PD properties PK properties Rivaroxaban
More informationNON-VITAMIN K ORAL ANTICOAGULANT REVERSAL
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationDisclosures. I have served as an advisory board member, consultant, speaker, and / or received research funding from: Sanofi-Aventis
TSOACs: Glee Lenoir, Pharm D. Pharmacy Clinical Coordinator The Medical Center Nursing Conference March 2015 Disclosures I have served as an advisory board member, consultant, speaker, and / or received
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationNew Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
More informationBlood products and pharmaceutical emergencies
Blood products and pharmaceutical emergencies Kasey L. Bucher PharmD, BCPS Clinical Specialist, Emergency Medicine Mercy Health Saint Mary s September 12, 2013 Disclosures None significancemagazine.com
More informationAnticoagulant Treatment for Deep Venous Thrombosis Direct Oral Anticoagulants (NOACs)
Anticoagulant Treatment for Deep Venous Thrombosis Direct Oral Anticoagulants (NOACs) Prof. P. HAINAUT Médecine Interne - Maladie Thromboembolique Cliniques Univ. Saint Luc - UCL Background Direct Oral
More informationNON-VITAMIN K ORAL ANTICOAGULANT REVERSAL
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationAdherence to NOACs. Disclosure. Patricia van den Bemt EAHP Hamburg 2015
Adherence to NOACs Patricia van den Bemt EAHP Hamburg 2015 Disclosure Unrestricted research grants from Glaxo-SmithKline Boehringer Ingelheim Daiichi Sankyo Bayer Pfizer For research on medication safety
More informationMaking Sense of the Newer Anticoagulants
Making Sense of the Newer Anticoagulants Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center I M FROM ARIZONA! DISCLOSURES No relevant
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More informationNovel OAC s : How should we use them?
Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker
More informationCritical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
More informationTroubled by warfarin s narrow therapeutic index, numerous
Jeremy W. Vandiver, PharmD, BCPS; Douglas Faulkner, MD; Michael Erlandson, MD; Mary Onysko, PharmD, BCPS University of Wyoming School of Pharmacy, Laramie (Drs. Vandiver and Onysko); Hampden Medical Group,
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationOut with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation
Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants
More informationDr Gordon Royle Haematologist, Middlemore Hospital
The New Oral Anticoagulants (NOACs) Dr Gordon Royle Haematologist, Middlemore Hospital Disclaimers Boehringer-Ingelheim Bayer Sanofi Douglas Pharmaceuticals Preventing disasters: lessons learned A cautionary
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationNo more rat poison? New oral anticoagulants and perioperative considerations
1 No more rat poison? New oral anticoagulants and perioperative considerations Jerrold H. Levy, MD, FAHA, FCCM Professor Department of Anesthesiology/Critical Care Duke University School of Medicine Durham,
More informationNew Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D.
New Oral Anticoagulants in the Management of Atrial Fibrillation June, 2012 By Deborah K Brokaw, Pharm.D. Introduction Since the 1950 s, the only orally available anticoagulant has been the vitamin K antagonist
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationManagement of atrial fibrillation. Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD
Management of atrial fibrillation Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD Antithrombotic therapy in atrial fibrillation Satchana Pumprueg, MD AF has serious consequences Independent
More informationDisclosure. Outline. Objectives. I have no actual or potential conflict of interest in relation to this presentation.
Disclosure I have no actual or potential conflict of interest in relation to this presentation. Sarah Lombardo, MD., MSc. General Surgery, University of Utah September 9, 2015 Objectives Outline Recognize
More informationBreadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationComparative Anticoagulation
Comparative Anticoagulation Laurajo Ryan, PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Austin College of Pharmacy The University of Texas Health Science Center Pharmacotherapy
More informationNOACs 2013: Evolving Anticoagulation Options. Erik Yeo MD University Health Network University of Toronto
NOACs 2013: Evolving Anticoagulation Options Erik Yeo MD University Health Network University of Toronto Objectives Clinical overview the new oral anticoagulants and their management issues Rivaroxaban
More information2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
More informationNovel OACs: How should we use them?"
Novel OACs: How should we use them?" Iqwal Mangat, MD FRCPC" Director, Arrhythmia Service, St. Michaelʼs Hospital" Assistant Professor of Medicine, University of Toronto" Presenter Disclosure Dr. Iqwal
More informationCONTEMPORARY REVERSAL OF ANTICOAGULATION
CONTEMPORARY REVERSAL OF ANTICOAGULATION Michael S. McHale, M.D., F.A.C.P. Avera Medical Group Hematology & Oncology Medications Coumadin / Warfarin Unfractionated Heparin Low Molecular Weight Heparin
More informationRecommendation for the Reversal of Novel Anticoagulants in Emergent Situations
Lauren Edwards PharmD Candidate 2016 Truman Medical Center, Lakewood Preceptor: Dr. Melissa Gabriel June 11, 2015 Recommendation for the Reversal of Novel Anticoagulants in Emergent Situations Background
More informationOral anticoagulants new and old: bleeding risk and management strategies. Logan Tinsen Pharm.D. Benefis Hospitals
Oral anticoagulants new and old: bleeding risk and management strategies Logan Tinsen Pharm.D. Benefis Hospitals Disclaimer! I am not receiving any compensation from any drug company! Any opinions I may
More information